140 related articles for article (PubMed ID: 34487727)
41. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
42. Moesin facilitates metastasis of hepatocellular carcinoma cells by improving invadopodia formation and activating β-catenin/MMP9 axis.
Lan S; Zheng X; Hu P; Xing X; Ke K; Wang F; Cheng N; Zhuang Q; Liu X; Liu J; Zhao B; Wang Y
Biochem Biophys Res Commun; 2020 Apr; 524(4):861-868. PubMed ID: 32057364
[TBL] [Abstract][Full Text] [Related]
43. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
44. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
45. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
46. DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway.
Deng Y; Lu L; Liang X; Li J; Zhu D; Huang H; Zhang Y; Zhang X; Chen Y; Liu X; Fu Y
Life Sci; 2023 Jan; 312():121266. PubMed ID: 36473542
[TBL] [Abstract][Full Text] [Related]
47. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
Tian T; Nan KJ; Guo H; Wang WJ; Ruan ZP; Wang SH; Liang X; Lu CX
Oncol Rep; 2010 Jun; 23(6):1593-600. PubMed ID: 20428814
[TBL] [Abstract][Full Text] [Related]
48. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Liu S; Zhang W; Liu K; Ji B; Wang G
Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
[TBL] [Abstract][Full Text] [Related]
49. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
50. As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.
Zhao Y; Yu Y; Zhao W; You S; Feng M; Xie C; Chi X; Zhang Y; Wang X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113871
[TBL] [Abstract][Full Text] [Related]
51. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
52. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
54. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
55. E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway.
Yu Y; Zhao D; Li K; Cai Y; Xu P; Li R; Li J; Chen X; Chen P; Cui G
Cell Death Dis; 2020 Apr; 11(4):273. PubMed ID: 32332880
[TBL] [Abstract][Full Text] [Related]
56. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
[TBL] [Abstract][Full Text] [Related]
57. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1.
Liu Y; Ding Y; Huang J; Wang S; Ni W; Guan J; Li Q; Zhang Y; Ding Y; Chen B; Chen L
PLoS One; 2014; 9(2):e88393. PubMed ID: 24551096
[TBL] [Abstract][Full Text] [Related]
58. DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway.
Zhang J; Shi Y; Ding K; Yu W; He J; Sun B
J Exp Clin Cancer Res; 2024 May; 43(1):136. PubMed ID: 38711082
[TBL] [Abstract][Full Text] [Related]
59. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
Hua H; Zhu Y; Song YH
Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
[TBL] [Abstract][Full Text] [Related]
60. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
Huang T; Guo YZ; Yue X; Zhang GP; Zhang Y; Kuang M; Peng BG; Li SQ
Carcinogenesis; 2020 Jul; 41(5):571-581. PubMed ID: 32649753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
